SK12299A3 - Fluorinated 1,4-disubstituted piperidine derivatives - Google Patents

Fluorinated 1,4-disubstituted piperidine derivatives Download PDF

Info

Publication number
SK12299A3
SK12299A3 SK122-99A SK12299A SK12299A3 SK 12299 A3 SK12299 A3 SK 12299A3 SK 12299 A SK12299 A SK 12299A SK 12299 A3 SK12299 A3 SK 12299A3
Authority
SK
Slovakia
Prior art keywords
hydroxy
phenylacetamide
piperidin
difluorocyclopentyl
amino
Prior art date
Application number
SK122-99A
Other languages
English (en)
Slovak (sk)
Inventor
Yoshimi Tsuchiya
Takashi Nomoto
Hirokazu Ohsawa
Kumiko Kawakami
Kenji Ohwaki
Masaru Nishikibe
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of SK12299A3 publication Critical patent/SK12299A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK122-99A 1996-08-01 1997-07-28 Fluorinated 1,4-disubstituted piperidine derivatives SK12299A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21943696 1996-08-01
JP5397997 1997-02-21
PCT/JP1997/002600 WO1998005641A1 (fr) 1996-08-01 1997-07-28 Derives de piperidine fluores a disubstitution en position 1,4

Publications (1)

Publication Number Publication Date
SK12299A3 true SK12299A3 (en) 2000-05-16

Family

ID=26394715

Family Applications (1)

Application Number Title Priority Date Filing Date
SK122-99A SK12299A3 (en) 1996-08-01 1997-07-28 Fluorinated 1,4-disubstituted piperidine derivatives

Country Status (29)

Country Link
US (2) US5948792A (fr)
EP (1) EP0930298B1 (fr)
JP (1) JP3063164B2 (fr)
KR (1) KR20000022214A (fr)
CN (1) CN1226888A (fr)
AR (3) AR008272A1 (fr)
AT (1) ATE229941T1 (fr)
AU (1) AU716050B2 (fr)
BG (1) BG103114A (fr)
BR (1) BR9711108A (fr)
CA (1) CA2261680C (fr)
CO (1) CO4960641A1 (fr)
CZ (1) CZ33199A3 (fr)
DE (1) DE69718026T2 (fr)
EE (1) EE9900038A (fr)
ES (1) ES2188961T3 (fr)
HR (1) HRP970426A2 (fr)
HU (1) HUP9902381A3 (fr)
ID (1) ID17259A (fr)
IL (1) IL127685A0 (fr)
IS (1) IS4960A (fr)
NO (1) NO990472D0 (fr)
NZ (1) NZ333842A (fr)
PE (1) PE92198A1 (fr)
PL (1) PL331431A1 (fr)
SK (1) SK12299A3 (fr)
TR (2) TR199900204T2 (fr)
WO (1) WO1998005641A1 (fr)
YU (1) YU1299A (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180823B1 (en) 1998-11-06 2001-01-30 Sepracor Inc. Stereoselective process for alkyl phenylglycolic acids
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
WO2000061572A1 (fr) * 1999-04-08 2000-10-19 Merck & Co., Inc. Preparation diastereoselective d'adduits de michael
WO2000066579A1 (fr) * 1999-04-28 2000-11-09 Banyu Pharmaceutical Co., Ltd. Methodes de preparation de derives de piperidylmethylpyridine
WO2001013918A1 (fr) * 1999-08-23 2001-03-01 H. Lundbeck A/S Traitement de l'incontinence urinaire
DE60021282T2 (de) 1999-12-07 2006-05-18 Theravance, Inc., South San Francisco Carbamat-derivate als muscarin-rezeptor antonisten
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
AU2525801A (en) * 1999-12-17 2001-06-25 Sanofi-Synthelabo Phenoxypropanolamines, method for producing them and pharmaceutical compositionscontaining them
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
US6469172B2 (en) 2000-03-08 2002-10-22 Merck & Co., Inc. Process for the preparation of chemical compounds
US6403584B1 (en) * 2000-06-22 2002-06-11 Merck & Co., Inc. Substituted nipecotyl derivatives as inhibitors of cell adhesion
EP1302458A4 (fr) * 2000-07-11 2005-10-19 Banyu Pharma Co Ltd Derives d'ester
NZ526580A (en) 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
DE60121813T2 (de) * 2000-12-28 2007-09-20 Almirall Ag Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
KR20040039436A (ko) * 2001-09-27 2004-05-10 파마시아 에이비 약학 조성물
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
AU2002345266B2 (en) 2002-07-08 2009-07-02 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
HK1079787A1 (zh) 2002-07-31 2006-04-13 Ranbaxy Laboratories Limited 用作毒蕈碱受体拮抗剂的3,6-二取代的氮杂双环[3.1.0]己烷衍生物
US6583103B1 (en) 2002-08-09 2003-06-24 S.C. Johnson & Son, Inc. Two part cleaning formula resulting in an effervescent liquid
WO2004014363A1 (fr) 2002-08-09 2004-02-19 Ranbaxy Laboratories Limited Derives d'azabicyclo[3.1.0] hexane 3,6-disubstitues, utiles en tant qu'agonistes de recepteurs muscariniques
EP1534675B1 (fr) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo(3.1.0)hexanes 3,6-disubstitues contenant fluoro et sulfonylamino, utilises comme antagonistes des recepteurs de muscarine
JP2006506392A (ja) * 2002-10-29 2006-02-23 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ムスカリン受容体アンタゴニストとしての第四級アンモニウム化合物
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
ATE400553T1 (de) * 2002-12-10 2008-07-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo 3.1.0 - hexanderivative als antagonisten des muscarinrezeptors
AU2003303041B2 (en) 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
AU2002347552A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
DE60225195T2 (de) 2002-12-23 2009-02-26 Ranbaxy Laboratories, Ltd. Flavaxat-derivate als muscarin-rezeptor antagonisten
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1618091A1 (fr) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
AU2003223010A1 (en) 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EA009059B1 (ru) 2003-04-10 2007-10-26 Рэнбакси Лабораториз Лимитед Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
JP2006522787A (ja) 2003-04-11 2006-10-05 ランバクシー ラボラトリーズ リミテッド ムスカリン様受容体アンタゴニストとしてのアザビシクロ誘導体
WO2004091597A2 (fr) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Procede pour traiter le syndrome du colon irritable
WO2005007645A1 (fr) 2003-07-11 2005-01-27 Theravance, Inc. Composes de 4-amino-1-benzylpiperidine substitues
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
BRPI0418212A (pt) * 2003-12-29 2007-04-27 Banyu Pharma Co Ltd composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade
WO2006005980A1 (fr) * 2004-06-16 2006-01-19 Ranbaxy Laboratories Limited Derives de xanthine utilises en tant qu'antagonistes du recepteur muscarinique
US20080262075A1 (en) * 2004-08-19 2008-10-23 Ranbaxy Laboratories Limited Pyrrolidine Derivatives as Muscarinic Receptor Antagonists
WO2006032994A2 (fr) * 2004-09-24 2006-03-30 Ranbaxy Laboratories Limited Antagonistes des recepteurs muscariniques
EP1797040A1 (fr) * 2004-09-29 2007-06-20 Ranbaxy Laboratories Limited Antagonistes de recepteurs muscariniques
RU2398773C2 (ru) 2004-11-02 2010-09-10 Баниу Фармасьютикал Ко., Лтд. Арилоксизамещенное производное бензимидазола
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
EP1828126A1 (fr) * 2004-12-15 2007-09-05 Ranbaxy Laboratories Limited Sels d'addition d'acide d'antagonistes du recepteur muscarinique
WO2006117754A1 (fr) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Derives d'azabicyclo [3.1.0] hexane 3,6-disubstitues utilises comme antagonistes du recepteur muscarinique
WO2007037534A1 (fr) * 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. Derive indole substitue en position 2 par un groupe heteroaryle
WO2007039884A1 (fr) * 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited Dérivés de 3 -azabicyclooctane en tant qu’antagonistes de récepteurs muscariniques
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
US20090010923A1 (en) * 2007-04-24 2009-01-08 University Of Maryland, Baltimore Treatment of cancer with anti-muscarinic receptor agents
JP5656288B2 (ja) * 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物
BRPI0820819B1 (pt) * 2007-12-21 2021-06-08 F. Hoffmann-La Roche Ag formulação de anticorpos humanizados b-ly 1 e seu uso
CN104876854B (zh) * 2015-04-16 2017-03-01 御盛隆堂药业有限责任公司 羟基乙酸酯衍生物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6018661B2 (ja) * 1976-01-01 1985-05-11 太田製薬株式会社 1−(1,3−ジオキソラン−4−イルメチル)ピペリジノ−ル誘導体
JPS5679688A (en) * 1979-12-04 1981-06-30 Ota Seiyaku Kk 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
CA2123728A1 (fr) * 1993-05-21 1994-11-22 Noriyoshi Sueda Derives de l'uree et leur utilisation comme inhibiteurs de l'acat
WO1995006635A1 (fr) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
JP3294961B2 (ja) * 1993-12-10 2002-06-24 杏林製薬株式会社 新規イミダゾール誘導体及びその製造法
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
US5750540A (en) * 1995-04-28 1998-05-12 Banyu Pharmaceutical Co., Ltd. 1,4-di-substituted piperidine derivatives
CA2179574A1 (fr) * 1995-06-26 1996-12-27 Tomomi Okada Derive de substitution de la piperidine et medicament a base de ce derive
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate

Also Published As

Publication number Publication date
AR016877A2 (es) 2001-08-01
EP0930298B1 (fr) 2002-12-18
AU3635197A (en) 1998-02-25
HUP9902381A2 (hu) 1999-11-29
AR017021A1 (es) 2001-08-22
DE69718026T2 (de) 2003-07-10
CA2261680C (fr) 2005-03-08
EE9900038A (et) 1999-08-16
NO990472L (no) 1999-02-01
PE92198A1 (es) 1999-01-09
AR008272A1 (es) 1999-12-29
TR199900204T2 (xx) 2000-01-21
PL331431A1 (en) 1999-07-19
WO1998005641A1 (fr) 1998-02-12
HUP9902381A3 (en) 2000-06-28
CN1226888A (zh) 1999-08-25
IL127685A0 (en) 1999-10-28
HRP970426A2 (en) 1998-08-31
YU1299A (sh) 2002-03-18
NO990472D0 (no) 1999-02-01
BG103114A (en) 1999-11-30
IS4960A (is) 1999-01-29
AU716050B2 (en) 2000-02-17
JP3063164B2 (ja) 2000-07-12
BR9711108A (pt) 1999-08-17
US6040449A (en) 2000-03-21
NZ333842A (en) 2001-05-25
TR200001482T2 (tr) 2000-11-21
US5948792A (en) 1999-09-07
ES2188961T3 (es) 2003-07-01
CO4960641A1 (es) 2000-09-25
ID17259A (id) 1997-12-11
EP0930298A4 (fr) 2000-06-07
ATE229941T1 (de) 2003-01-15
DE69718026D1 (de) 2003-01-30
CZ33199A3 (cs) 1999-07-14
EP0930298A1 (fr) 1999-07-21
KR20000022214A (ko) 2000-04-25
CA2261680A1 (fr) 1998-02-12

Similar Documents

Publication Publication Date Title
US6040449A (en) Fluorine-containing 1, 4-disubstituted piperidine derivatives
JPWO1998005641A1 (ja) 含フッ素1,4−ジ置換ピペリジン誘導体
AU700837B2 (en) 1,4-di-substituted piperidine derivatives
EP0863141B1 (fr) Derives heteroaromatiques substitues
US5942523A (en) Compounds which are selective antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
EP0532456B1 (fr) Dérivés de l'acyle-1-pipéridine et leur utilisation comme antagonistes du substance P
WO2003103669A1 (fr) 1-(4-piperidinyl) benzimidazolones utilises en tant qu'antagonistes du recepteur h3 de l'histamine
DE69630717T2 (de) 1-acyl-3-phenyl-3-(3-piperidinopropyl)piperidinderivate als für den menschlichen nk3-rezeptor selektive antagonisten
EP1556372B1 (fr) 4-amino-1-(pyridylmethyl) piperidine substituee et composes associes
JP2001039950A (ja) N−アシル環状アミン誘導体
WO1997045414A1 (fr) Derives de piperidine a disubstitution en positions 1,4
JP3282618B2 (ja) 含フッ素1,4−ジ置換ピペリジン誘導体の新規製造中間体
JP3282617B2 (ja) 含フッ素1,4−ジ置換ピペリジン誘導体の新規製造中間体
HK1020341A (en) Fluorinated 1, 4-disubstituted piperidine derivatives
MXPA99000965A (en) Fluorinated 1,4-disubstituted piperidine derivatives
JP2993124B2 (ja) 1,4−ジ置換ピペリジン誘導体
JPWO1997045414A1 (ja) 1,4−ジ置換ピペリジン誘導体
KR100339444B1 (ko) 타키키닌길항제로서 유용한 치환된 피롤리딘-3-일-알킬-피페리딘
JPWO1997013766A1 (ja) 置換ヘテロ芳香環誘導体
JPWO1996033973A1 (ja) 1,4−ジ置換ピペリジン誘導体
HK1118824A (en) Substituted heterocyclic compounds, method for preparing same and pharmaceutical compositions containing them